Related Experiment Video
Updated: Mar 21, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
[Expression and Significance of Pim-3 Gene in Acute Myeloid Leukemia]
Zhen-Cang Zhou1, Zu-Guo Tian2, Zhong Yuan2
1Department of Hematology, The First People's Hospital of Zunyi, Zunyi 563003, Guizhou Province, China.
Objective:
To investigate the role of Pim-3 abnomal expression in development of acute myeloid leukemia.
Methods:
Semi-quantitative RT-PCR was used to detect the expression of Pim-3 in bone marrow of 47 newly diagnosed and untreated patients with acute myeloid leukemia (AML) and 18 patients with AML after treatment with chemotherapy. At the same time, the bone marrow of 10 cases of non-hematologic malignancies was used as normal control. The difference of the Pim-3 gene expression in bone marrows among the 3 groups was also compared.
Results:
According to the RT-PCR detection results, the Pim-3 expression level in bone marrow of AML patients before chemotherapy were all significantly lower than those in patients with non-hematologic malignancies (P < 0.01). After chemotherapy, there were no significant differences of the Pim-3 expression level between the patients with acute myeloid leukemia and non-hematologic malignancies (P > 0.05), but the Pim-3 expression level was significantly lower in patients before chemotherapy as compared with that in patients post chemotherapy (P < 0.01). The comparison of Pim-3 expression before and after chemotherapy in remission group showed that Pim-3 expression levels before chemotherapy were all significantly lower than those after chemotherapy (P < 0.01), but there were no significant differences of Pim-3 expression levels between patients before and after chemotherapy in non-remission group (P > 0.05). The Pim-3 expression levels of non-remission patients after chemotherapy were all significantly lower than those of the remission patients after chemotherapy (P < 0.01).
Conclusion:
Pim-3 gene is abnormally expressed in the AML patients before and after chemotherapy, and this gene may be involved in the genesis and development of acute myeloid leukemia.
Insights
Pim-3 gene expression is significantly lower in acute myeloid leukemia (AML) patients before chemotherapy compared to healthy controls. This abnormal expression may play a role in AML development.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- Understanding the molecular mechanisms underlying AML development is crucial for targeted therapies.
Purpose of the Study:
- To investigate the role of Pim-3 gene expression in the development of acute myeloid leukemia (AML).
Main Methods:
- Semi-quantitative RT-PCR was employed to assess Pim-3 gene expression.
- Bone marrow samples were analyzed from newly diagnosed AML patients, post-chemotherapy AML patients, and non-hematologic malignancy controls.
Main Results:
- Pim-3 expression was significantly lower in AML patients before chemotherapy compared to controls (P < 0.01).
- Post-chemotherapy, Pim-3 levels in AML patients showed no significant difference from controls, but were higher than pre-chemotherapy levels (P < 0.01).
- In remission patients, Pim-3 levels increased post-chemotherapy (P < 0.01), unlike non-remission patients. Non-remission patients had lower post-chemotherapy Pim-3 levels than remission patients (P < 0.01).
Conclusions:
- Abnormal Pim-3 gene expression is observed in acute myeloid leukemia patients both before and after chemotherapy.
- The Pim-3 gene may be implicated in the genesis and progression of acute myeloid leukemia.
